Collegium Pharmaceutical, Inc is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Collegium Pharmaceutical, Inc valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $808m, up 14.3% on a year earlier, slower than the 19.9% growth a quarter earlier. Free-cash-flow margin rose to 40.6% from 28.5% a year earlier. It passes 2 of our 7 financial-health checks.
Our model value for Collegium Pharmaceutical is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Collegium Pharmaceutical, Inc's trailing-twelve-month revenue grew 14.3% year on year, with a free-cash-flow margin of 40.6%.
Our discounted-cash-flow model values the business at ~$300 per share in the base case (~$230–$400 across growth scenarios) — model values under stated assumptions, not a price target.
Current signal Free cash flow diverging from earnings: TTM free cash flow grew 62.7% while net income fell 7.6%: a 70pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The company also guided to jornay pm revenue, net of $190.00m to $200.00m for the full-year 2026; azstarys revenue, net of $65.00m to $75.00m for the full-year 2026.
Our value per share comes from a discounted-cash-flow model of Collegium Pharmaceutical, Inc's free cash flow after stock-based pay ( $338M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Collegium Pharmaceutical, Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.5%: the 10-year Treasury yield (4.9%) plus a beta of 0.78 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. | ~$300 ~$230–$400 | Left out: out of range vs price (12.70x) |
| Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$67 ~$68–$130 | Left out: far from the other models (more than 3x away from their median) |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Collegium Pharmaceutical, Inc with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Now |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | $15.57 | $18.46 | $17.17 | $20.58 | $20.03 | $18.68 | $23.20 | $30.78 | $28.65 | $46.30 | $23.68 |
| Market value | $378m | $559m | $566m | $688m | $704m | $767m | $785m | $1.3bn | $1.2bn | $1.8bn | $900m |
| + Net debt (− = net cash) | −$149m | −$119m | −$135m | −$159m | −$75m | −$46m | −$33m | $23m | $167m | $7m | $109m |
| Enterprise value | $229m | $440m | $431m | $530m | $630m | $720m | $752m | $1.3bn | $1.3bn | $1.8bn | $1.0bn |
| Multiples | |||||||||||
| Price / sales | n/m | 19.6x | 2.0x | 2.3x | 2.3x | 2.8x | 1.7x | 2.3x | 1.8x | 2.4x | 1.1x |
| Price / earnings | — | — | — | — | 26.3x | 10.7x | — | 26.7x | 16.7x | 29.2x | 26.9x |
| Price / free cash flow | — | — | 3.5x | 32.3x | 8.0x | 7.5x | 6.4x | 4.7x | 5.7x | 5.6x | 2.7x |
| EV / EBITDA | — | — | — | — | 11.0x | 37.2x | 20.9x | 7.7x | 7.6x | 10.0x | 6.2x |
Moderate moat
How hard Collegium Pharmaceutical's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Cash operating profit has been a median 5.4% of total assets over 7 years.
Gross margin has been a median 56.7%, moving by 6.6 percentage points (standard deviation) across 7 years.
Operating margin has been a median 10.7%; its worst year was -1322.8%.
Free cash flow was positive in 9 of 10 years, at a median 29.9% of revenue.
The diluted share count fell 0.6% over five years; stock-based pay has been a median 5.9% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (53 before it).
Next results: November 5, 2026, before the open. Analysts expect revenue of $216m and EPS of $1.86 (range $1.72 to $1.97) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $7.46 | +1% | $833m | +7% |
| Next | $7.26 | −3% | $845m | +1% |
Next year's EPS estimate has moved −3.4% in 90 days, across 7 analysts.
The consensus EPS forecast for the current fiscal year is −4.2% on 90 days ago. In the last 30 days, 0 analysts raised Collegium Pharmaceutical, Inc's forecast and 1 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | $7.78 | $7.51 |
| 60 days ago | $7.53 | $6.97 |
| 30 days ago | $7.37 | $6.62 |
| 7 days ago | $7.34 | $6.65 |
| Now | $7.46 | $7.26 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $1.76 | $1.92 | +8.8% |
| Mar 2026 | $1.52 | $1.76 | +15.5% |
| Dec 2025 | $2.14 | $2.04 | −4.7% |
| Sept 2025 | $1.86 | $2.25 | +21.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Our cash-flow model grows Collegium Pharmaceutical, Inc's revenue by +6.8% next year and +10.4% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+3.8%, weight 53%) , management guidance (+4.6%, weight 20%) and the company's own record (+14.5%, weight 27%) . How the weights are set.
Last 12 months −34.2%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $707m | $808m | +14.3% |
| Net margin | 5.1% | 4.1% | −19.2% |
| P/E multiple | 37.8x | 26.9x | −28.9% |
| Share count | 38m | 38m | +0.1% |
Biggest factor: p/e multiple.
Last 3 years +6.7%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $537m | $808m | +50.5% |
| P/S multiple | 1.5x | 1.1x | −25.9% |
| Share count | 36m | 38m | −4.4% |
Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| COLL | −7% | +24% | +33% | −7% | +62% | −49% |
| Industry peers (median) | −20% | −52% | −14% | −2% | +7% | −12% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| COLL | 42% | 58% | 42% | 42% | 67% | 27% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| COLL | −33% | −37% | −30% | −32% | −27% | −56% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 74% from December 30, 2015 to May 8, 2017. Getting back needed a 279% gain, reached on March 8, 2018, 304 days after the low.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 6, 2026 | −17.5% | +0.5% | −21.2% | −34.2% |
| May 7, 2026 | +3.5% | +0.5% | −4.6% | −8.9% |
| February 26, 2026 | −8.9% | −1.0% | −18.5% | −29.1% |
| November 6, 2025 | +18.0% | −1.0% | +29.4% | +33.6% |
| August 7, 2025 | +17.4% | +0.7% | +24.9% | +26.9% |
| May 8, 2025 | +6.8% | +0.6% | +8.5% | +12.5% |
| February 27, 2025 | +2.5% | −0.1% | +5.1% | +4.8% |
| November 7, 2024 | −6.8% | +1.2% | −12.3% | −11.3% |
| August 8, 2024 | +2.5% | +2.8% | +2.4% | +5.9% |
| July 29, 2024 | +7.0% | −0.4% | −4.3% | +4.7% |
| May 9, 2024 | −17.2% | +0.7% | −11.5% | −12.5% |
| February 22, 2024 | +14.5% | +2.1% | +15.6% | +25.1% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $546.6M |
| FY23 Q4 | $566.8M |
| FY24 Q1 | $566.9M |
| FY24 Q2 | $576.7M |
| FY24 Q3 | $599.2M |
| FY24 Q4 | $631.4M |
| FY25 Q1 | $664.3M |
| FY25 Q2 | $707M |
| FY25 Q3 | $757.1M |
| FY25 Q4 | $780.6M |
| FY26 Q1 | $796.3M |
| FY26 Q2 | $808.2M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q3 | 51.1% |
| FY23 Q4 | 22.2% |
| FY24 Q1 | 8.0% |
| FY24 Q2 | 7.4% |
| FY24 Q3 | 9.6% |
| FY24 Q4 | 11.4% |
| FY25 Q1 | 17.2% |
| FY25 Q2 | 22.6% |
| FY25 Q3 | 26.3% |
| FY25 Q4 | 23.6% |
| FY26 Q1 | 19.9% |
| FY26 Q2 | 14.3% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q3 | 21.4% |
| FY23 Q4 | 29.5% |
| FY24 Q1 | 33.8% |
| FY24 Q2 | 35.3% |
| FY24 Q3 | 32.3% |
| FY24 Q4 | 26.9% |
| FY25 Q1 | 21.4% |
| FY25 Q2 | 18.4% |
| FY25 Q3 | 20.7% |
| FY25 Q4 | 23.0% |
| FY26 Q1 | 23.7% |
| FY26 Q2 | 19.5% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY23 Q3 | 48.8% |
| FY23 Q4 | 48.4% |
| FY24 Q1 | 54.4% |
| FY24 Q2 | 47.8% |
| FY24 Q3 | 32.1% |
| FY24 Q4 | 32.2% |
| FY25 Q1 | 29.6% |
| FY25 Q2 | 28.5% |
| FY25 Q3 | 38.2% |
| FY25 Q4 | 42.0% |
| FY26 Q1 | 41.4% |
| FY26 Q2 | 40.6% |
Each dollar Collegium Pharmaceutical took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.
| Revenue | $781M | |
|---|---|---|
| Cost of revenue | $317M | 40.7% of revenue |
| Gross profit | $463M | 59.3% of revenue |
| Selling, general and admin | $285M | 36.5% of revenue |
| Operating income | $180M | 23.0% of revenue |
| Income tax | $29.7M | 3.8% of revenue |
| Interest and other | $87M | 11.1% of revenue |
| Net income | $62.9M | 8.1% of revenue |
| Fiscal year | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | |||||||||||
| Revenue | 2 | 28 | 280 | 297 | 310 | 277 | 464 | 567 | 631 | 781 | 808 |
| Gross profit | 1 | 26 | 115 | 103 | 180 | 151 | 209 | 326 | 377 | 463 | 485 |
| EBITDA | −93 | −75 | −20 | −23 | 57 | 19 | 36 | 170 | 174 | 184 | 162 |
| Operating income | −94 | −75 | −21 | −24 | 56 | 18 | 33 | 167 | 170 | 180 | 157 |
| Net income | −94 | −75 | −39 | −23 | 27 | 72 | −25 | 48 | 69 | 63 | 34 |
| Diluted EPS | −$3.88 | −$2.47 | −$1.19 | −$0.68 | $0.76 | $1.86 | −$0.74 | $1.29 | $1.86 | $1.73 | $0.88 |
| Growth (year on year) | |||||||||||
| Revenue | — | +>999% | +884.7% | +5.8% | +4.5% | −10.7% | +67.6% | +22.2% | +11.4% | +23.6% | +14.3% |
| EBITDA | — | — | — | — | — | −66.1% | +85.9% | +373.5% | +1.9% | +5.8% | +20.7% |
| Operating income | — | — | — | — | — | −68.7% | +89.0% | +401.1% | +1.8% | +5.7% | +21.3% |
| Net income | — | — | — | — | — | +167.3% | −135.0% | — | +43.7% | −9.1% | −7.6% |
| Diluted EPS | — | — | — | — | — | +144.7% | −139.8% | — | +44.2% | −7.0% | −7.5% |
| Margins | |||||||||||
| Gross margin | 87.6% | 90.9% | 40.9% | 34.7% | 58.0% | 54.4% | 45.2% | 57.5% | 59.8% | 59.3% | 60.0% |
| EBITDA margin | <−999% | −262.9% | −7.0% | −7.8% | 18.4% | 7.0% | 7.8% | 30.1% | 27.5% | 23.5% | 20.0% |
| Operating margin | <−999% | −264.9% | −7.4% | −8.0% | 18.1% | 6.4% | 7.2% | 29.5% | 26.9% | 23.0% | 19.5% |
| Net margin | <−999% | −262.9% | −14.0% | −7.7% | 8.6% | 25.8% | −5.4% | 8.5% | 11.0% | 8.1% | 4.1% |
| Free-cash-flow margin | <−999% | −238.8% | 58.5% | 7.2% | 28.5% | 36.7% | 26.4% | 48.4% | 32.2% | 42.0% | 40.6% |
| Cash flow | |||||||||||
| Cash from operations | −75 | −67 | 169 | 28 | 94 | 104 | 124 | 275 | 205 | 329 | 330 |
| Capital spending | 0 | 1 | 5 | 6 | 6 | 2 | 2 | 0 | 2 | 2 | 2 |
| Free cash flow | −76 | −68 | 164 | 21 | 88 | 102 | 123 | 274 | 203 | 328 | 328 |
| Stock-based pay | 6 | 8 | 14 | 17 | 22 | 24 | 23 | 27 | 32 | 42 | 45 |
| Free cash flow after stock pay | −81 | −76 | 150 | 5 | 66 | 77 | 100 | 247 | 171 | 286 | 283 |
| Balance sheet | |||||||||||
| Cash | 153 | 119 | 147 | 170 | 174 | 186 | 174 | 239 | 71 | 231 | 129 |
| Total debt | 4 | — | 12 | 12 | 100 | 140 | 141 | 262 | 237 | 238 | 239 |
| Net debt (negative = net cash) | −149 | −119 | −135 | −159 | −75 | −46 | −33 | 23 | 167 | 7 | 109 |
| Diluted shares | 24m | 30m | 33m | 33m | 35m | 41m | 34m | 42m | 40m | 40m | 38m |
| Returned to shareholders | |||||||||||
| Buybacks | — | — | — | — | — | 48 | 14 | 75 | 60 | 25 | — |
| Total returned | — | — | — | — | — | 48 | 14 | 75 | 60 | 25 | — |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 159 | 182 | 178 | 188 | 209 | 205 | 194 | 200 |
| Gross profit | 97 | 98 | 97 | 108 | 129 | 128 | 117 | 110 |
| EBITDA | 36 | 39 | 23 | 36 | 63 | 62 | 31 | 6 |
| Operating income | 35 | 38 | 22 | 35 | 62 | 61 | 31 | 4 |
| Net income | 9 | 13 | 2 | 12 | 17 | 17 | 14 | −15 |
| Diluted EPS | $0.27 | $0.36 | $0.07 | $0.34 | $0.84 | $0.46 | $0.40 | −$0.46 |
| Growth (year on year) | ||||||||
| Revenue | +16.5% | +21.5% | +22.7% | +29.4% | +31.4% | +12.9% | +8.9% | +6.3% |
| EBITDA | −21.9% | −37.5% | −54.8% | −25.2% | +76.4% | +57.5% | +37.7% | −84.8% |
| Operating income | −22.6% | −38.2% | −56.2% | −26.0% | +78.2% | +59.4% | +42.5% | −89.5% |
| Net income | −54.8% | −60.8% | −91.3% | −38.9% | +83.3% | +35.3% | — | −225.6% |
| Diluted EPS | −49.1% | −56.1% | −90.1% | −34.6% | +211.1% | +27.8% | — | −235.3% |
| Margins | ||||||||
| Gross margin | 60.8% | 54.0% | 54.8% | 57.7% | 61.7% | 62.5% | 60.6% | 55.2% |
| EBITDA margin | 22.5% | 21.5% | 12.8% | 19.3% | 30.1% | 30.0% | 16.2% | 2.8% |
| Operating margin | 21.9% | 20.9% | 12.2% | 18.7% | 29.7% | 29.6% | 16.0% | 1.9% |
| Net margin | 5.9% | 6.9% | 1.4% | 6.4% | 8.2% | 8.3% | 7.5% | −7.5% |
| Free-cash-flow margin | −5.8% | 46.2% | 30.7% | 38.5% | 37.4% | 59.6% | 29.4% | 35.4% |
| Cash flow | ||||||||
| Cash from operations | −9 | 85 | 55 | 72 | 78 | 123 | 57 | 71 |
| Capital spending | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Free cash flow | −9 | 84 | 55 | 72 | 78 | 122 | 57 | 71 |
| Stock-based pay | 7 | 8 | 12 | 11 | 10 | 10 | 11 | 14 |
| Free cash flow after stock pay | −17 | 76 | 43 | 62 | 68 | 113 | 46 | 56 |
| Last 12 months unless stated | COLL | CORT | SUPN | AXSM | PCRX | AMPH | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $808m | $831m | $865m | $865m | $746m | $730m | $296m |
| Revenue growth, last 12 months | 14.3% | 16.0% | 26.9% | 54.2% | 5.7% | 1.0% | 10.0% |
| Revenue growth, 3-year average | 14.6% | 24.7% | 12.3% | 57.0% | 3.7% | 10.5% | 5.9% |
| Revenue growth, latest quarter | 6.3% | 31.7% | 18.0% | 51.9% | 6.2% | 5.4% | 6.4% |
| Gross margin | 60.0% | 98.3% | 87.6% | — | 79.2% | 47.7% | 60.1% |
| Operating margin | 19.5% | 0.8% | −5.7% | −17.5% | 2.7% | 15.7% | −5.9% |
| Operating margin, 3-year average | 24.4% | 12.5% | −0.7% | −48.6% | 0.4% | 24.3% | −6.4% |
| Net margin | 4.1% | 6.6% | −5.1% | −18.2% | 2.0% | 10.8% | −7.0% |
| Cash from operations / revenue | 40.8% | 13.2% | 10.2% | −9.5% | 25.2% | 25.3% | 10.8% |
| Free-cash-flow margin | 40.6% | 12.9% | 10.1% | −9.5% | 24.1% | 20.9% | 9.3% |
| Free-cash-flow margin, 3-year average | 39.0% | 19.9% | 15.6% | −22.3% | 22.5% | 20.5% | 7.4% |
| Stock pay / revenue | 5.6% | 10.7% | 4.1% | 11.5% | 7.5% | 4.0% | 3.7% |
| Change in share count | −0.1% | −2.2% | 2.8% | 4.7% | −2.8% | −7.8% | 1.9% |
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Belbuca | $222M | 28.4% | ▲ 4.9% |
| Xtampza ER | $199M | 25.5% | ▲ 4.2% |
| Jornay Pm | $149M | 19.1% | ▲ 299.7% |
| Nucynta IR | $115M | 14.8% | ▲ 14.5% |
| Nucynta ER | $81M | 10.4% | ▲ 6.9% |
| Symproic and Other | $14.5M | 1.9% | ▼ 4.3% |
From Collegium Pharmaceutical, Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Blackrock, Inc. | $197M | 5.4M | 13.8% | ▲ 6.0% |
| Jupiter Topco LLC | $77.7M | 2.1M | 5.4% | — |
| Invesco Ltd. | $68.1M | 1.9M | 4.8% | ▲ 18.3% |
| Fuller & Thaler Asset Management, Inc. | $59.1M | 1.6M | 4.1% | ▲ 8.9% |
| Principal Financial Group Inc | $59.1M | 1.6M | 4.1% | ▲ 26.0% |
| State Street Corp | $55.3M | 1.5M | 3.9% | ▲ 7.3% |
| Massachusetts Financial Services Co | $50.9M | 1.4M | 3.6% | ▲ 2.9% |
| Vanguard Capital Management LLC | $50M | 1.4M | 3.5% | ▲ 3.5% |
| Renaissance Technologies LLC | $49.5M | 1.4M | 3.5% | ▼ 7.0% |
| Eventide Asset Management, LLC | $49.3M | 1.4M | 3.4% | ▼ 4.4% |
| Rubric Capital Management LP | $46.3M | 1.3M | 3.2% | 0.0% |
| Geode Capital Management, LLC | $32.3M | 891K | 2.3% | ▲ 8.7% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Collegium Pharmaceutical, Inc's complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Freund John Gordon Director | May 18, 2026 | Sell | 20 | $34.05 | $681 |
| Freund John Gordon Director | May 15, 2026 | Sell | 4,127 | $34.54 | $142,547 |
| Lurker Nancy Director | May 13, 2026 | Sell | 4,500 | $35.97 | $161,865 |
| Bohlin Garen G Director | May 11, 2026 | Sell | 8,700 | $37.18 | $323,466 |
| Dieter David EVP & General Counsel | March 18, 2026 | Sell pre-set plan | 13,976 | $34.92 | $488,042 |
| Dieter David EVP & General Counsel | March 9, 2026 | Sell pre-set plan | 6,224 | $36.65 | $228,110 |
| Dreyer Scott EVP & Chief Commercial Officer | March 3, 2026 | Sell pre-set plan | 46,417 | $40.36 | $1.9M |
| Dreyer Scott EVP & Chief Commercial Officer | March 3, 2026 | Sell pre-set plan | 3,559 | $40.99 | $145,883 |
| Dreyer Scott EVP & Chief Commercial Officer | December 8, 2025 | Sell pre-set plan | 6,475 | $48.66 | $315,074 |
| Dreyer Scott EVP & Chief Commercial Officer | December 8, 2025 | Sell pre-set plan | 11,125 | $47.89 | $532,776 |
| Balice-Gordon Rita J. Director | December 5, 2025 | Sell | 3,650 | $47.03 | $171,660 |
| Fallon John A. Director | November 12, 2025 | Sell | 34,853 | $47.21 | $1.6M |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
